MarketInOut Stock Screener Log In | Sign Up
 

Innate Pharma S.A. ADR

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026
Innate Pharma S.A. ADR stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization175.37 mln
Float111 mln
Earnings Date03/25/2027

Piotroski F-Score

1 / 9
Very weak

Beneish M-Score

12.92
Highly suspicious

Relative Strength

29 / 100
Underperforming

Pre-Tax Margin

-1,765%
Severely loss-making

ROE

153
Extraordinary

Altman Z-Score

-10.79
Deeply distressed

Business Description

Founded in 1999 and headquartered in Marseille, France, Innate Pharma is a clinical-stage biotechnology company focused on developing cancer treatments that work by activating the body's immune system. Its pipeline includes several antibody-based therapies targeting blood cancers and solid tumors, with key programs in late-stage clinical trials conducted in partnership with major pharmaceutical companies such as AstraZeneca, Sanofi, and Novo Nordisk. The company's research spans multiple approaches to fighting cancer, from blocking pathways that suppress immune responses to engaging natural killer cells to attack tumor cells.

Key Fundamentals

EPS-0.59
ROE153
RPS0.01
ROIC-128
ROA-55.31
Interest Cover-17.47
EBITDA, mln-60.71
EV / EBITDA-3.33
EV / EBIT-3.24
Revenue, mln3.13
EV / Revenue64.59

Quote Details

Last 1.50
Change 0 (0%)
Open 1.49
Volume 11,577
Turnover 17,366
Average Volume 36,512

Financial Ratios

Pre-Tax Profit Margin-1,765
Current Ratio1.27
Price / Sales52.85

Financial Strength

Altman Z-Score-10.79
Piotroski F-Score 1 / 9
Beneish M-Score12.92
Short Ratio1.92
Short % of Float0.08

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 4.9% 88 / 100   
1 Month -11.76% 27 / 100   
2 Months -13.29% 28 / 100   
6 Months 6.38% 76 / 100   
1 Year -28.57% 26 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog